

1 **A unifying model to explain high nirmatrelvir therapeutic efficacy against SARS-CoV-2,**  
2 **despite low post-exposure prophylaxis efficacy and frequent viral rebound**  
3

4  
5 **Authors**

6 Shadisadat Esmaeili,<sup>1\*</sup> Katherine Owens,<sup>1†</sup> Jessica Wagoner,<sup>2</sup> Stephen J. Polyak,<sup>2</sup> Judith M.  
7 White,<sup>3</sup> Joshua T. Schiffer<sup>1,2</sup>  
8

9 **Affiliations**

10 <sup>1</sup>Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center; Seattle, WA, USA.

11 <sup>2</sup>Department of Medicine, University of Washington; Seattle, WA, USA.

12 <sup>3</sup>Department of Cell Biology, University of Virginia; Charlottesville, VA, USA.

13 \*Corresponding Author: [sesmaeil@fredhutch.org](mailto:sesmaeil@fredhutch.org)

14 † These authors contributed equally to this work.  
15

16 **Abstract**

17 In a pivotal trial (EPIC-HR), a 5-day course of oral ritonavir-boosted nirmatrelvir, given early  
18 during symptomatic SARS-CoV-2 infection (within three days of symptoms onset), decreased  
19 hospitalization and death by 89.1% and nasal viral load by 0.87 log relative to placebo in high-  
20 risk individuals. Yet, nirmatrelvir/ritonavir failed as post-exposure prophylaxis in a trial, and  
21 frequent viral rebound has been observed in subsequent cohorts. We developed a mathematical  
22 model capturing viral-immune dynamics and nirmatrelvir pharmacokinetics that recapitulated  
23 viral loads from this and another clinical trial (PLATCOV). Our results suggest that  
24 nirmatrelvir's *in vivo* potency is significantly lower than *in vitro* assays predict. According to  
25 our model, a maximally potent agent would reduce the viral load by approximately 3.5 logs  
26 relative to placebo at 5 days. The model identifies that earlier initiation and shorter treatment  
27 duration are key predictors of post-treatment rebound. Extension of treatment to 10 days for  
28 Omicron variant infection in vaccinated individuals, rather than increasing dose or dosing  
29 frequency, is predicted to lower the incidence of viral rebound significantly.  
30  
31

## 32 Introduction

33 The SARS-CoV-2 main protease inhibitor nirmatrelvir is a drug plagued by  
34 contradictions. In a landmark, randomized, double-blinded, placebo-controlled clinical  
35 trial with 1364 analyzed individuals, 300 mg of nirmatrelvir boosted with 100 mg  
36 ritonavir was given twice daily for five days to high-risk individuals with SARS-CoV-2  
37 infection within 3 days of developing symptoms. Compared to placebo, nirmatrelvir  
38 reduced the combined outcome of hospitalization and death by 89%, eliminated death  
39 as an outcome, and reduced viral load by 0.87 log after 5 days of treatment<sup>1</sup>. This  
40 critical result prompted the Food and Drug Administration (FDA) to issue an  
41 Emergency Use Authorization<sup>2</sup>. The drug became the most widely prescribed antiviral  
42 for SARS-CoV-2 in the United States, likely preventing thousands of hospitalizations  
43 and many deaths<sup>3</sup>. Ritonavir boosted nirmatrelvir was recently licensed by the FDA  
44 based on its continued effectiveness and safety<sup>4</sup> and has outperformed other antivirals  
45 in terms of hospitalization and viral load reduction<sup>5</sup>.

46 However, the use of nirmatrelvir/ritonavir in real-world cohorts has identified viral  
47 rebound as a significant issue. Viral rebound occurred in 14.2% of individuals in one  
48 large cohort and was usually associated with recrudescence of symptoms, though  
49 protection against hospitalization and death appeared to be maintained<sup>6</sup> and remains  
50 significant despite high rates of population immunity due to vaccination and prior  
51 infection<sup>7</sup>. Similar rates of viral rebound were observed between molnupiravir and  
52 nirmatrelvir, suggesting the rebound effect is not drug-specific and may pertain to  
53 characteristics of SARS-CoV-2 infection and treatment duration<sup>8</sup>. This high incidence  
54 of viral rebound exceeded the 2.3% rate observed in the proof-of-concept trial, which  
55 did not differ from placebo<sup>9</sup>.

56 Despite its high efficacy as an early symptomatic therapy for high-risk individuals,  
57 nirmatrelvir/ritonavir was not authorized for use as post-exposure prophylaxis (PEP). In  
58 a clinical trial of post-exposure prophylaxis, nirmatrelvir/ritonavir showed 32% and  
59 37% reductions in symptomatic COVID-19 relative to placebo when given for five or  
60 ten days respectively<sup>10</sup>. However, neither of these results reached statistical  
61 significance. Notably, molnupiravir, another drug that reduced hospitalization when  
62 given during early symptomatic infection, also failed as post-exposure prophylaxis<sup>11</sup>.  
63 Only long-acting monoclonal antibodies have demonstrated efficacy for post-exposure  
64 prophylaxis<sup>12-14</sup>, but these are no longer active against prevalent circulating strains<sup>15</sup>.

65 Early during the COVID-19 pandemic, multiple groups employed mathematical models  
66 to simulate the outcomes of clinical trials for SARS-CoV-2<sup>16-22</sup>. These models all  
67 accurately predicted that antiviral therapy that was insufficiently potent or given too  
68 late during infection might fail to provide clinical benefit<sup>16-19,21</sup>. Our previous modeling  
69 results further suggested that viral rebound may occur and was more likely if a drug  
70 was dosed during the pre-symptomatic phase of infection when viral loads are still  
71 expanding, as occurs in a post-exposure prophylaxis scenario<sup>23</sup>. The proposed  
72 mechanism of this effect was that reducing viral load may blunt early immune  
73 responses and preserve susceptible cells, allowing viral re-expansion upon cessation of  
74 treatment that was of insufficient potency to eliminate all infected cells<sup>24</sup>. The model  
75 suggested that this phenomenon could theoretically occur during early symptomatic  
76 treatment as well. At the time, we downplayed the significance of model-generated  
77 rebound as the phenomenon had yet to be demonstrated clinically. However, models fit  
78 to rebound data now suggest a similar mechanism of action<sup>25</sup>.

79 Here we use an updated model for SARS-CoV-2 viral kinetics that was first validated  
80 against a much larger panel of untreated individuals to precisely simulate the virologic  
81 outcomes of two nirmatrelvir/ritonavir trials. We identify that the true *in vivo* potency  
82 of nirmatrelvir is significantly less than its *in vitro* potency, such that drug levels are  
83 sub-therapeutic during a portion of the dosing interval. Viral rebound is observed in our  
84 simulations and is more likely when the drug is dosed early during infection and is not  
85 reduced with a higher dose or dosing frequency. Extended-duration treatment is  
86 identified as the best strategy to avoid viral rebound.

87

## 88 Results

### 89 Viral Dynamic, Pharmacokinetic, and Pharmacodynamic Mathematical models

90 To derive parameters for simulating nasal viral loads in the absence of therapy, we used  
91 the mechanistic mathematical model (**Fig 1a**) that best recapitulated 1510 SARS-CoV-  
92 2 infections in a cohort of 1440 SARS-CoV-2 infected individuals from the National  
93 Basketball Association cohort<sup>26</sup>. The model assumes a finite number of susceptible  
94 cells. An eclipse phase delays viral production by infected cells. In keeping with an  
95 early interferon-mediated innate immune response, susceptible cells can become  
96 refractory to infection in the presence of infected cells but also revert to a susceptible  
97 state at a constant rate. Infected cells are cleared by cytolysis, a constant early immune  
98 response rate, and delayed acquired immunity, which is activated in a time-dependent  
99 fashion. We used a mixed-effect population approach implemented in Monolix to  
100 estimate model parameters (**Fig S1, Table S1**).

101 To reproduce levels of nirmatrelvir, we used a two-compartment pharmacokinetic (PK)  
102 model (Error! Reference source not found.**b**). Using Monolix and the mixed-effect  
103 population approach, we estimated parameter values by fitting the model to the plasma  
104 concentration of healthy subjects. The model closely recapitulated observed drug levels  
105 following a single dose of 250mg/100mg of nirmatrelvir/ritonavir (**Fig S2, Table S2**).  
106 The effect of ritonavir as a metabolic inhibitor is accounted for in nirmatrelvir's  
107 clearance rate in the PK model. We also fit the model to population-level plasma  
108 concentrations following a single dose of 250mg/100mg and 750mg/100mg, showing  
109 that estimated parameters are dose-independent (**Table S3**).

110 For the pharmacodynamic (PD) model, we assumed drug efficacy follows a Hill  
111 equation with respect to concentration. We parameterized the model using *in vitro*  
112 efficacy data collected at different concentrations of nirmatrelvir (details in **Materials**  
113 **and Methods, Fig S3, Table S4**).

114 Finally, we combined the viral dynamic and PKPD models by using treatment efficacy  
115 to lower the viral production rate (details in **Materials and Methods, Fig 1**). We fit the  
116 combined model to viral load drop from baseline reported in two randomized,  
117 controlled trials: the EPIC-HR trial with 1574 high-risk unvaccinated symptomatic  
118 individuals<sup>1</sup> (**Fig 2**) and the PLATCOV trial with 144 low-risk, symptomatic  
119 individuals (**Fig 3a-e**)<sup>5</sup>. We also fit the combined model to individual viral load data  
120 from PLATCOV (**Fig 3f-h, Fig S4 & Fig S5, Table S5**).

### 121 Mathematical model fitting to clinical trial virologic outcome data

122 The *in vivo* potency of a drug is often different from values measured *in vitro*<sup>23,28,29</sup>. We  
123 define the *in vivo* IC<sub>50</sub> as the plasma drug concentration required to inhibit viral  
124 replication by 50% and the potency reduction factor (prf) as the ratio between the *in*

125 *vivo* and *in vitro* IC<sub>50</sub>. To identify the *in vivo* potency of nirmatrelvir, we estimated the  
126 prf using two methods.

127 For the first method, we simulated virtual cohorts using the combined viral dynamic-  
128 PKPD model and fit the results to viral load decay from baseline in two trials. For each  
129 trial arm, we randomly selected 400 individuals from the NBA cohort with the closest  
130 matching viral variant, symptom, and vaccine status (unvaccinated symptomatic  
131 subgroup for EPIC-HR and symptomatic Omicron infection for PLATCOV) and used  
132 their estimated individual viral dynamic parameters in simulations. This approach  
133 generated a wide, realistic range of shedding kinetic patterns among simulated  
134 participants (**Fig S1**).

135 We next addressed variability in the timing of baseline viral load measurement relative  
136 to infection. We randomly assigned all individuals an incubation period selected from a  
137 variant-specific gamma distribution found in the literature.<sup>27</sup> Treatment start day was  
138 randomly selected from a uniform distribution for each individual within 3 days of  
139 symptom onset for EPIC-HR trial and within 4 days for the PLATCOV trial.

140 For all simulated individuals in the treatment arm, PK parameters were randomly  
141 drawn from the estimated lognormal population parameter distributions (**Table S2**) and  
142 PD parameters from a normal distribution with estimated mean and standard error  
143 (**Table S4**). To estimate the prf, we simulated our virtual cohort treated with 300 mg of  
144 nirmatrelvir twice per day for five days with a range of values and selected the prf that  
145 generated the best agreement between the average change from baseline in the  
146 treatment arm of each trial and each simulation.

147 Our simulations recapitulated the mean change in viral load from baseline to multiple  
148 timepoints during the two weeks following study enrollment in EPIC-HR (Error!  
149 Reference source not found.**a**) and PLATCOV (**Fig 3a**). Similarly, with optimized prf  
150 estimates, the model closely recapitulated mean viral load reduction in the treatment  
151 arms of both trials (**Figs 2b and 3b**).

152 Our model also predicted individual-level variability in virologic responses observed in  
153 PLATCOV, including instances of increased viral load following therapy. We  
154 compared simulated and actual distributions of viral load change among trial  
155 participants in the control and treatment arms. On most post-treatment days, simulated  
156 and actual distributions were not statistically dissimilar (**Fig 3d, e**). Wider distributions  
157 of observed versus simulated viral load change were noted on post-randomization days  
158 1 and 2 for control and days 1 and 4 for treatment (**Fig 3d, e**), perhaps due to noise in  
159 viral load data from oral swabs: differences of 1-2 logs were often noted between  
160 replicates collected from PLATCOV participants at equivalent timepoints, particularly  
161 on day 1 and 2 (**Fig S6**).

## 162 **Reduction of *in vivo* nirmatrelvir potency relative to *in vitro***

163 We plotted the coefficient of determination, R<sup>2</sup>, for fit to viral load data assuming  
164 different prf values (**Figs 2c and 3c**). The best values (prf=61 for EPIC-HR and prf=37  
165 for PLATCOV) were determined by maximizing the R<sup>2</sup> of the fit. We repeated the  
166 simulation 10 times: the boxplot in the lower panel of **Figs 2c and 3c** represents the  
167 standard error of the prf average value and does not reflect individual variability.

168 The reason for slight differences in estimated prfs between the two trials is unknown.  
169 Possible explanations include different sampling methods (nasal swabs in EPIC-HR  
170 versus oropharyngeal swabs in PLATCOV), different trial participant characteristics

171 (high-risk adults in EPIC-HR versus lower-risk adults without comorbidities in  
172 PLATCOV), and differing dominant viral variants between the trials.

### 173 **Mathematical model fitting to individual viral load trajectories in PLATCOV**

174 For the second method, we fit the combined viral dynamic-PKPD model to individual  
175 viral load data from the PLATCOV trial. Since samples were collected after  
176 enrollment, we also included data from symptomatic Omicron-infected individuals in  
177 the NBA cohort to inform the population model about viral expansion rates during  
178 early infection. We used a mixed-effect population approach in Monolix to estimate  
179 each participant's viral dynamic parameters and their potency reduction factor (prf)  
180 (details in **Materials and Methods**). Our model closely recapitulated viral load  
181 trajectories, including cases with post-treatment rebound (**Fig 3f-g**). The estimated  
182 individual prf values were lognormally distributed, with a median of 39.79 (IQR 27.25-  
183 55.75, range 13.51-105.03) (**Fig 3h, Table S5**).

184 The estimated population distribution of viral load parameters for Omicron-infected  
185 individuals of the NBA cohort and the PLATCOV trial were the same except for  $\phi$  (a  
186 proxy for the innate immune response),  $\tau$  (timing of the adaptive immune response),  
187 and  $t_0$  (infection time) (**Fig S7**). Time is measured relative to the day of detection in the  
188 NBA cohort and relative to the day of baseline measurement in the PLATCOV trial, so  
189 the larger  $t_0$  and  $\tau$  values for PLATCOV reflect the delay between infection and trial  
190 enrollment. The reason for slight differences in estimated  $\phi$  values between the two  
191 groups is unknown but might be due to the different sampling methods (nasal swabs for  
192 NBA versus oropharyngeal swabs for PLATCOV).

193 To further validate our model, we ran counterfactual simulations switching the  
194 PLATCOV treatment and control arms (**Fig S8 c & d**). We treated participants in the  
195 control arm of the trial (treatment counterfactual) and removed treatment from  
196 participants in the treatment arm (control counterfactual). Due to treatment effect, onset  
197 of the adaptive immune response was not easily identifiable for the treatment arm.  
198 Therefore, when running the control counterfactual simulation, we assigned random  
199  $\tau$  values from the estimated control arm distribution. Counterfactual simulations  
200 reproduced the mean viral load drop from baseline observed in the trial (**Fig S8a & b**)  
201 and predicted a diversity of responses to treatment. In some cases, treatment lowered  
202 the peak and shortened infection (**Fig S8c(I) & d(III)**), while in other cases, treatment  
203 had a more limited effect (**Fig S8c(IV) & d(II)**). Our results suggest that some  
204 individuals with treatment-induced rebound may not have rebounded in their  
205 counterfactual case (**Fig S8c(III)**), while some untreated individuals with persistent  
206 infection might have experienced a treatment-induced rebound (**Fig S8d(I)**).

207

### 208 **Estimates of viral load reduction with an optimal drug**

209 To illustrate the importance of estimating *in vivo* drug potency, we compared the PKPD  
210 projection and average change in viral load of treatment arms with prf=1 (no reduction  
211 in potency) and prf=61 (as estimated in the EPIC-HR trial). With an approximately 61-  
212 fold weaker potency, drug levels dropped below therapeutic level shortly after each  
213 dose, due to its short half-life ( $t_{1/2}$ ), and antiviral effect subsided within a day after  
214 treatment ended maintaining an average efficacy of 82% (**eq. 3**) over the first 5 days of  
215 treatment (**Fig 2d, e**). However, the plasma concentration of a perfectly potent drug  
216 (prf=1) remained above therapeutic levels for the duration of treatment with a 5-day  
217 average efficacy of 99.99% and the effect persisted for nearly 10 days (**Fig 2e**). If the *in*  
218 *vivo* potency perfectly matched the measured *in vitro* potency (prf=1), the same

219 treatment regimen could reduce the viral load by approximately 3.5 logs at day 5  
220 relative to the placebo compared to the 0.87 log reduction reported in the trial (**Fig 2f**).  
221 While estimating nirmatrelvir's *in vitro* PD parameters, we assumed only the  $IC_{50}$   
222 differs *in vivo*. To confirm the validity of this assumption, we simulated the treatment  
223 arm of EPIC-HR with different combinations of the prf and the Hill coefficient. **Fig S9**  
224 shows that the best fit always happened for prf  $\sim 60$  and was mostly independent of the  
225 Hill coefficient.

226 The potency reduction factor was more sensitive to certain PK parameters (**Fig S10**),  
227 particularly the drug's clearance rate ( $\kappa_{CL}$ ). If the drug was cleared from the body more  
228 rapidly-then it would need to be more potent to achieve the effect observed in the  
229 clinical trial. However, this did not impact our alternate dosing regimen simulations  
230 since PK parameters were independent of the dose (**Table S3**).

### 231 **Frequent viral rebound on nirmatrelvir**

232 To assess whether our model generated viral rebound, we assumed cohort  
233 characteristics compatible with the PLATCOV trial (**Fig 3**) and randomly drew  
234 individual prf values from the distribution obtained by fitting individual data (**Fig 3h**,  
235 **Table S5**). We simulated from infection to 30 days after symptom onset, monitoring  
236 viral load continually. We defined rebound in the control arm as any case with at least  
237 two peaks in viral load with height greater than 3 logs and higher than its preceding  
238 minimum by at least 1 log (**Fig S11a**). We defined rebound in the treatment arm as any  
239 instance in which a post-treatment viral load exceeded the viral load at the end of the  
240 treatment by 1 log (**Fig S11b**).

241 By this definition, we observed rebound in 18.15% of cases treated with the clinical  
242 trial dose and 1.75% of controls in our simulations (**Fig 4b**). When a less sensitive  
243 equivalent definition of rebound was used as in the trial (1 log increase in viral load 5  
244 days after treatment cessation), the probability of rebound in the simulation was much  
245 lower (4.12% if treatment was assumed to begin several days after symptoms), closer to  
246 that of the controls, and comparable to that observed in the trial (**Fig S12**).

### 247 **Limited impact of nirmatrelvir dose or dosing frequency on viral rebound**

248 We next explored different treatment regimens to estimate their impact on lowering  
249 viral load and the chance of rebound. We simulated therapy with 150, 300, 600, and  
250 900 mg doses administered twice per day for 5 days, starting within 3 days post  
251 symptom onset. Larger doses decreased viral load more significantly and quickly than  
252 300 mg twice daily. 900 mg of nirmatrelvir reduced viral load by a mean of 2 logs on  
253 day 2 and a mean of 4 logs on day 5 compared to the control (**Fig 4a**).

254 Individual viral loads were highly variable within each treatment group regardless of  
255 dose (**Fig 4a**) due to heterogeneous underlying viral dynamics (**Fig S1**) and different  
256 treatment timing. Responses to treatment also differed substantially according to viral  
257 load trajectory and treatment timing (**Fig 4c**). The reduction in viral load was almost  
258 always greater during the first 5 days of treatment with higher doses. However, this  
259 only impacted viral elimination in certain cases (**Fig 4c,i**). Sometimes, viral load  
260 equilibrated to similar levels post-treatment regardless of dose (**Fig 4c, ii**), while in  
261 other cases, higher doses were associated with rebound (**Fig 4c, iv**). By achieving a  
262 lower post-treatment viral load nadir, higher doses resulted in a greater likelihood of  
263 viral rebound in our simulations (**Fig 4b**).

264 Increasing the frequency of antiviral dosing had nearly equivalent effects to increasing  
265 the dose: a more rapid reduction in viral load (**Fig S13a**), heterogeneous effects based

266 on individual viral dynamics and treatment timing (**Fig S13c**), and increased chance of  
267 rebound (**Fig S13b**).

## 268 **Early treatment as a predictor of SARS-CoV-2 rebound**

269 We next simulated therapy with four different treatment initiation windows: post-  
270 exposure prophylaxis (PEP): 0-1 day after infection in the pre-symptomatic phase;  
271 early treatment: 0-1 day after symptom onset as often occurs in community settings;  
272 intermediate treatment: 1-5 days after symptom onset as in the clinical trial; and late  
273 treatment: 5-10 days after symptom onset. In all simulations, the administered dosage  
274 was 300mg twice per day for 5 days.

275 Applying treatment as PEP or shortly after symptoms lowered viral load more  
276 substantially relative to control than intermediate or late therapy at days 2 and 5 post-  
277 treatment, though intermediate and late strategies also significantly lowered viral load  
278 relative to control at these time points (**Fig 5a**). However, PEP and early treatment were  
279 associated with higher rebound probability after treatment (**Fig 5b, c**). The boxplots for  
280 control groups in each panel in **Fig 5a** show the viral load at different points during  
281 infection and are matched to different timing of nirmatrelvir in the treatment arms.

## 282 **Prolongation of treatment to reduce the probability of SARS-CoV-2 rebound**

283 Next, we analyzed the impact of treatment duration on viral rebound. We simulated  
284 treatment regimens with 300mg nirmatrelvir twice per day for 2, 5, 10, 15, and 20 days.  
285 Treatment was initiated within 3 days after symptoms appeared. **Fig 6a** demonstrates  
286 the continuous drop in viral load if treatment was maintained until infection was  
287 effectively cleared. The viral load distributions of the treatment arms with 15 and 20  
288 days of treatment on days 2, 5, and 10 matched the viral load distribution of the  
289 treatment arm with 10 days of treatment duration and, therefore, are not shown.  
290 Prolonging treatment duration to 10 days almost eliminated viral rebound (**Fig 6b & c**).

291 We next explored the impact of treatment duration given different treatment initiation  
292 time. Prolonging treatment to 15 days for early treatment and 20 days for PEP lowered  
293 the viral load close to the limit of detection (1.26 log) at the end of treatment and  
294 eliminated the probability of rebound for Omicron variants (**Fig 7**).

## 295 **Differing observed rebound rates resulting from varying timing of sampling and** 296 **definitions**

297 Previous studies defined rebound using criteria with varying virologic thresholds,  
298 timing, and sampling frequency<sup>9</sup>. Rebound was sometimes defined when a positive test  
299 followed a negative test<sup>30</sup>. In EPIC-HR, treatment started within 5 days of symptoms  
300 onset (our intermediate treatment group) and rebound was defined as a 0.5 log increase  
301 on days 10 and/or 14. By this definition 2.3% of treated cases were classified as  
302 rebound<sup>9</sup>. The probability of rebound in our simulation with a threshold of 0.5 log  
303 measured only on day 5 after the end of the treatment was 5.45% and decreased as  
304 thresholds for viral rebound increased (**Fig S12**). This percentage would be even lower  
305 if treatment started 3-5 days after symptoms (rather than 1-5 days) because rebound  
306 probability is very sensitive to treatment timing. We hypothesize that in EPIC-HR,  
307 participant enrollments skewed later during the 5-day post-symptom window.

308 In our simulations, we recorded viral load every 0.001 of a day and used a 1 log  
309 threshold to identify rebound cases. This was a more sensitive method to observe  
310 rebound and suggests that in trial and real-world cohorts, rebound is likely more  
311 common in treated individuals than is detected with less frequent sampling (**Fig S12**).

312

### 313 **Higher rebound probability in unvaccinated individuals with pre-Omicron variant** 314 **infection**

315 All simulations reported in **Figures 3-7** were performed assuming symptomatic,  
316 vaccinated individuals with Omicron infection in the NBA cohort or PLATCOV. We  
317 repeated simulations with characteristics compatible with the EPIC-HR trial  
318 (unvaccinated symptomatic individuals with pre-Omicron variants) and prf values  
319 randomly drawn from the distribution obtained in **Fig 2c**. The same patterns of rebound  
320 probability were observed for altered treatment regimens. However, our model  
321 predicted an overall higher rebound probability in unvaccinated individuals, infected by  
322 pre-Omicron variants (**FigS14**). While 10 days of treatment would be sufficient to  
323 lower the rebound probability significantly in the vaccinated individuals with Omicron  
324 infection, 15 days of treatment would have been necessary to substantially lower the  
325 incidence of rebound in unvaccinated individuals in the pre-omicron era.

326

### 327 **Immune and viral mechanisms for viral rebound**

328 To understand mechanisms that might explain higher rebound incidence in the PEP and  
329 early treatment groups, we simulated four treatment arms with treatment starting on  
330 days 1, 4, 7, and 10 after infection. Treatment start relative to infection was fixed to  
331 limit the added variability introduced by incubation period and timing of treatment  
332 relative to symptoms in previous simulations. High frequency of rebound with day 1  
333 and day 4 treatment start was evident from viral load after treatment (**Fig 8a** top row) in  
334 many individual trajectories (grey lines) and to a less dramatic extent in mean viral load  
335 (blue line). A second peak after treatment ended was also seen in infected cells (**Fig 8a**  
336 middle row, blue line) and the intensity of the innate immune response (the rate of  
337 production of refractory cells) (**Fig 8a** bottom row).

338 Applying treatment earlier during infection (day 1 and 4 in our simulations) lowered  
339 the viral load and the populations of infected and refractory cells, preserving  
340 susceptible cells. In the earlier treatment groups the ratio of susceptible to refractory  
341 cells was significantly higher at the end of the treatment than it was in the control group  
342 at equivalent time points (**Fig 8b**). Innate immune responses were significantly  
343 diminished in treated individuals versus controls due to fewer infected cells (**Fig 8c**).  
344 Overall, a weaker innate immune response, higher availability of susceptible cells, and  
345 persistence of infected cells after 5 days of treatment allowed viral rebound after  
346 treatment cessation.

347 We previously partitioned the NBA cohort according to shedding kinetics using k-  
348 means clustering<sup>26</sup>. Groups were ordered by the area under their viral load curve  
349 (AUC), with group 1 having the smallest AUC and group 6 the largest (**Fig S15a**). We  
350 simulated treatment with different initiation days using these 6 groups and identified  
351 the highest rebound probability in the earlier treatment groups when treating infections  
352 that would have fast initial virus expansion (upslope) and high peak viral load (groups  
353 2, 4, and 6) without treatment (**Fig S15b, c**).

354

### 355 **Discussion**

356 We previously demonstrated for HSV-2<sup>31</sup>, HIV<sup>32</sup>, Ebola virus<sup>28</sup>, and SARS-CoV-2<sup>23</sup>,  
357 that considering the timing and intensity of the immune response is vital to accurately  
358 simulate clinical trials of antiviral agents. If a direct-acting antiviral therapy is given too



359 late during infection, then efficacy is often low because the disease is driven by excess  
360 inflammation and cytokine storm. On the other hand, concurrent immune pressure can  
361 provide critical assistance for antiviral agents to eliminate viral replication, as  
362 confirmed in recent studies<sup>7</sup>. Accordingly, previous modeling suggested that extremely  
363 early treatment of pre-symptomatic SARS-CoV-2 as occurs with PEP requires higher  
364 drug potency than treatment during early symptomatic infection because innate  
365 immunity is more active at this slightly later stage of infection and fewer susceptible  
366 cells remain<sup>23</sup>. It is increasingly clear that the potency and duration of antiviral therapy  
367 required to achieve clinical benefit depends strongly on the stage of infection and the  
368 ongoing intensity of the immune response.

369 Prior work also demonstrated that *in vitro* antiviral drug potency measured in cell  
370 culture often overestimates *in vivo* potency in humans<sup>28,29,33</sup>. Specifically, the plasma  
371 drug level required to achieve 50% inhibition of cellular infections *in vivo* is higher  
372 than the level required *in vitro*. The discrepancy between *in vitro* and *in vivo* potency  
373 can be assessed by fitting viral dynamic-PKPD mathematical models to viral load data  
374 from clinical trials, as we have done here. Traditional PKPD models, which do not  
375 include a dynamic immune response, are not sufficient to estimate *in vivo* potency.  
376 Because *in vivo* potency reduction varies from 2 to 100 depending on the infection and  
377 antiviral agents<sup>28,31,33</sup>, population *in vivo* IC<sub>50</sub> must be assessed separately in each case.

378 Here, by precisely fitting a combined viral-immune dynamic / PKPD model to viral  
379 load data from a randomized clinical trial as well as an open-label clinical trial of  
380 nirmatrelvir/ritonavir, we merge these two key concepts. We first identify that  
381 nirmatrelvir potency is reduced 60-70 fold *in vivo* relative to *in vitro* in the high-risk  
382 population and 30-40 fold in the healthy population. The difference between the  
383 estimated *in vivo* potency in these two populations might be explained by differences in  
384 demographics, sampling methods, and the dominant viral variants in the two trials.  
385 However, both values fall within the range of inter-individual variability estimated by  
386 fitting the model to the individual viral loads of the second trial. The mechanistic  
387 reasons for this reduction cannot be determined by the model, but may include  
388 increased *in vivo* protein binding<sup>34</sup>, inhibition of drug delivery from plasma to sites of  
389 infection, or differences in cellular uptake and drug metabolism *in vivo*<sup>35</sup>. Nevertheless,  
390 our estimated *in vivo* IC<sub>50</sub> provides a benchmark plasma level to target in future trials.  
391 The PKPD model also demonstrates that the drug's relatively short half-life allows it to  
392 dip to subtherapeutic levels even when dosed twice daily.

393 Our model also develops a viable hypothesis for why nirmatrelvir is highly effective  
394 when given during early symptomatic infection but less so when given as post-exposure  
395 prophylaxis. By preventing a high peak viral load approximately 3-5 days after  
396 infection, therapy preserves susceptible cells and blunts the immediate, likely innate  
397 immune response to SARS-CoV-2, while not eliminating infected cells. If the virus is  
398 not eliminated by an early acquired response along with antiviral pressure, it rebounds  
399 to a peak level that is sometimes comparable to the initial peak. We hypothesize that  
400 viral rebound occurs more frequently in community settings relative to the clinical trial,  
401 because infected individuals in the community are often prescribed the drug very early  
402 after symptom development, whereas in the trial, there was a natural 1 to 2-day delay  
403 based on the enrollment and consent process. Surprisingly, this short delay may have  
404 limited rebound while not affecting the primary endpoints of the trial, a finding  
405 supported by recent clinical studies<sup>30</sup>, which nevertheless still suggests a clear benefit  
406 for earlier treatment in terms of preventing hospitalization in high-risk individuals<sup>7</sup>.  
407 Notably, antiviral therapy is not a risk factor for rebound in our model or in clinical

408 cohorts if administered late during infection<sup>36</sup>. However, high viral load shedding is a  
409 risk factor for rebound in our model, as suggested in other studies<sup>37</sup>.

410 Our model identifies optimal conditions for viral rebound, which, counterintuitively,  
411 include early treatment during pre-symptomatic infection and higher or more frequent  
412 dosing. Both factors suppress the amount of infection, thereby preserving susceptible  
413 cells, limiting the development of refractory cells, and dampening the intensity of the  
414 early immune response. The best method to prevent viral rebound is prolonging  
415 treatment, with a longer course needed for PEP. This finding is consistent with trials of  
416 long-acting monoclonal antibodies, which demonstrated efficacy as post-exposure  
417 prophylaxis<sup>12-14</sup>.

418 Because our model is validated precisely against mean viral load reduction from two  
419 trials as well as individual viral kinetics it can be used as a tool to test treatment  
420 strategies varied therapeutic goals, timing of treatment, dose, dosing interval, and  
421 duration of therapy. Our prior PD modeling also allows testing of potentially  
422 synergistic agent combinations and consideration of special hosts such as  
423 immunocompromised individuals with persistent infection who may be at risk of  
424 developing drug resistance<sup>28,38,39</sup>. We believe our approach provides a template for  
425 optimizing future trial designs with nirmatrelvir and other therapies.

426 Our model has several limitations. First, nasal or oropharyngeal viral load is not a  
427 perfect surrogate of disease activity. On the one hand, viral load reduction has been  
428 correlated with beneficial clinical outcomes for nirmatrelvir<sup>1</sup>, molnupiravir<sup>40</sup>, and  
429 monoclonal antibodies<sup>41</sup>. A recent review shows that viral load reduction is a  
430 reasonably good surrogate endpoint<sup>41</sup>. Moreover, viral rebound appears to track very  
431 closely with symptomatic rebound in multiple case series<sup>9</sup>. Yet, early remdesivir  
432 treatment provided a profound reduction in hospitalization while not impacting nasal  
433 viral load, albeit 5 days after completion of therapy<sup>42</sup>. Data from non-human primates  
434 suggests that the drug has a specific effect on viral loads in the lungs that is not  
435 observed in upper airways, a finding that we were also<sup>23</sup>. Overall, there is a strong  
436 suggestion from early treatment trials that a reduction in nasal viral loads beyond that  
437 observed in placebo-treated individuals is associated with substantial clinical benefit<sup>1</sup>.

438 Another limitation is that the model does not account for drug resistance. While there  
439 has been limited evidence of de novo resistance during nirmatrelvir therapy, serial  
440 passage of virus suggests a relatively low barrier, and some viral rebound could, in  
441 theory, be with resistant variants. Studies to date suggest very little mutational change  
442 between the infecting and rebounding virus<sup>43-46</sup>.

443 Our model does not capture immunity in literal terms. For instance, we do not  
444 distinguish innate interferon, antibody, and T-cell responses, as these have not been  
445 measured in sufficient longitudinal detail to precisely ascribe viral clearance to different  
446 components of the immune response. We structured the model for the early response to  
447 roughly map to innate responses, as the model term capturing the progression of  
448 susceptible cells to a refractory state diminishes with decreases in viral load and  
449 assumes no immune memory. The late immune response in our model has memory,  
450 leads to rapid elimination of the virus, and is likely to represent acquired immunity.  
451 While a more accurate model would discriminate different arms of the immune  
452 responses and fit to immune data, ours sufficiently captures the timing and intensity of  
453 immune responses for accurate clinical trial simulation.

454 Finally, it is our opinion that models lacking a spatial component cannot fully describe  
455 target cell limitation, which is influenced by the packing structure of cells, viral

456 diffusion, and infection within multiple concurrent micro-environments<sup>31</sup>.  
457 Consequently, ordinary differential equations may misclassify the relative impact of  
458 target cell limitation and innate immune responses in the period surrounding peak viral  
459 load. However, our approach provides accurate output for clinical trial simulation.

460 In conclusion, our model identifies viable mechanistic underpinnings of the high  
461 efficacy of nirmatrelvir therapy for early symptomatic SARS-CoV-2 infection, lower  
462 efficacy for PEP, and high incidence of viral rebound in a real-world setting. The model  
463 can also be used to assess different treatment strategies and suggests prolonging therapy  
464 is the optimal method to avoid rebound while maintaining potent early antiviral  
465 suppression.  
466

## 467 **Materials and Methods**

### 468 **Study Design**

469 We developed a viral dynamics model recapitulating viral load data collected from  
470 symptomatic individuals in the NBA (National Basketball Association) cohort<sup>47</sup>. We  
471 used a two-compartment model to reproduce the PK data of nirmatrelvir plus ritonavir<sup>2</sup>.  
472 For clinical trial simulation, we constructed a virtual cohort by randomly selecting 400  
473 individuals from the NBA cohort, trying to match the trial populations regarding  
474 vaccine status and history of infection, and assigning individual PK and PD parameters  
475 randomly drawn from their respective inferred distributions. We fit the combined viral  
476 dynamic and PKPD model to the average change in viral load from the baseline as well  
477 as individual viral load data of the control and treatment arms of two previously  
478 published nirmatrelvir/ritonavir clinical trials<sup>1,5</sup>. Comparing our model to the control  
479 arms validated our viral dynamic model and demonstrated how well our virtual cohorts  
480 represent the trial control arms. As one method of fitting the treatment arms, we used  
481 the average data from the treatment arms to estimate the potency reduction factor (prf)  
482 by maximizing the  $R^2$  of the fit. In a second approach, we fit to individual viral load  
483 trajectories in PLATCOV using the mixed-effect population approach implemented in  
484 Monolix and obtained both individual prf values and a population distribution. With the  
485 estimated prf and *in vivo*  $IC_{50}$  of the drug, we explored different treatment regimens by  
486 changing dose, dosing frequency, treatment duration, and treatment timing to find the  
487 best strategy to minimize the probability of rebound.

### 488 **Viral load data**

489 The NBA cohort dataset published by Hay et al<sup>47</sup> consists of 2875 documented SARS-  
490 CoV-2 infections in 2678 people detected through frequent PCR testing regardless of  
491 symptoms. We used the viral load data from 1510 infections in 1440 individuals that  
492 had at least 4 positive quantitative samples to estimate viral dynamic parameters. We  
493 used parameter sets estimated for the symptomatic subpopulation of these individuals  
494 to construct virtual cohorts.

### 495 **Clinical trial data**

496 We used viral load data from two nirmatrelvir/ritonavir clinical trials. EPIC-HR by  
497 Hammond et al.<sup>1</sup> included 682 and 697 symptomatic high-risk individuals in the control  
498 and treatment arms, respectively. We obtained the average change in viral load data of  
499 the control and treatment arms by digitizing Figure 3A of the manuscript by Hammond  
500 et al.<sup>1</sup>. Nasal viral load was measured using PCR assay on days 0, 3, 5, 10, and 14 after  
501 the treatment start day and adjusted by the baseline viral load. PLATCOV by Schilling  
502 et al.<sup>5</sup> is an open-label, randomized, controlled adaptive trial with 85 and 59

503 symptomatic, young, healthy individuals in the control and nirmatrelvir treatment arms,  
504 respectively. The oropharyngeal samples from each participant were collected daily on  
505 days 0 through 7 and on day 14 after the treatment start day, and viral load was  
506 measured using PCR assay. We used the individual viral load data published by the  
507 authors. From PLATCOV, we averaged over the two oral samples collected from each  
508 individual and calculated viral load drop from baseline (to use in method 1, Figure 3) or  
509 used the individual-level viral load data (in method 2, Figure 3). In both trials, the study  
510 participants were treated with 300mg/100mg nirmatrelvir/ritonavir within three days  
511 (EPIC-HR) or four days (PLATCOV) of symptom onset. The treatment was  
512 administered twice per day, for five days. We used EPIC-HR's lower limit of detection  
513 (LOD = 2 logs imputed as 1 log) in the simulations where we used EPIC-HR cohort  
514 characteristics (unvaccinated symptomatic individuals) (Figures S9, S10, and S14).  
515 When fitting to PLATCOV cohort characteristics (vaccinated symptomatic individuals  
516 with omicron infection) and in all the simulations in the main paper, we used the  
517 maximum LOD reported in the published data (~1.26 log).

### 518 **PK data**

519 PK data of nirmatrelvir (PF-07321332) with ritonavir was obtained by digitizing Figure  
520 4 of the drug's Emergency Use Authorization document<sup>2</sup> using WebPlotDigitizer<sup>48</sup>.  
521 The data is from a phase I randomized trial by Singh et al.<sup>49</sup> where eight participants (4  
522 fed, 4 fasting) took a single dose of 250mg/100mg nirmatrelvir/ritonavir. Drug  
523 concentrations in plasma were recorded for 48 hours following dosing.

### 524 **PD data**

525 The data on drug efficacy experiments performed at the University of Washington. The  
526 efficacy of nirmatrelvir in the presence of CP-100356 (an efflux inhibitor<sup>50</sup>) was  
527 measured against the delta variant of SARS-CoV2 in Calu-3 cells (human lung  
528 epithelial). The efflux inhibitor ensures consistent, adequate intracellular levels of drug.  
529 Briefly, Calu 3 cells were treated with varying concentrations of nirmatrelvir in the  
530 presence of 2uM CP-100356 prior to infection with SARS-CoV-2 (delta isolate) at a  
531 multiplicity of infection of 0.01. Antiviral efficacy and cell viability (of non-infected  
532 cells treated with drugs) were assessed as described<sup>51</sup>. There were five replicates per  
533 condition, pooled from 2 independent technical experimental repeats (one experiment  
534 with triplicate conditions, one experiment in duplicate conditions).

### 535 **Viral dynamics model**

536 We used our model of SARS-CoV-2 dynamics<sup>26</sup> to model the viral load of  
537 symptomatic individuals with SARS-CoV-2 infection. Our model assumes that  
538 susceptible cells ( $S$ ) are infected at rate  $\beta VS$  by SARS-CoV-2 virions. The infected  
539 cells go through a non-productive eclipse phase ( $I_E$ ) before producing viruses and  
540 transition to becoming productively infected ( $I_P$ ) at rate  $\kappa I_E$ . When encountering  
541 productively infected cells, the susceptible cells become refractory to infection ( $R$ ) at  
542 the rate  $\phi I_P S$ . Refractory cells revert to a susceptible state at rate  $\rho R$ . The productively  
543 infected cells produce virus at the rate  $\pi I_P$  and are cleared at rate  $\delta I$  representing  
544 cytolysis and the innate immune response that lacks memory and is proportional to the  
545 amount of ongoing infection. If the infection persists longer than time  $\tau$ , then cytotoxic  
546 acquired immunity is activated, which is represented in our model by the rate  $m I_P$ .  
547 Finally, free virions are cleared at the rate  $\gamma$ . Of note, this model, previously proposed  
548 by Ke et al.<sup>52</sup>, was selected against other models in<sup>26</sup> based on superior fit to data and  
549 parsimony. The model written as a set of differential equations has the form,

550

$$551 \quad \frac{dS}{dt} = -\beta SV - \phi I_P S + \rho R \quad (1a)$$

$$552 \quad \frac{dR}{dt} = \phi I_P S - \rho R \quad (1b)$$

$$553 \quad \frac{dI_E}{dt} = \beta SV - \kappa I_E \quad (1c)$$

$$554 \quad \frac{dI_P}{dt} = \kappa I_E - \delta I_P - m(t)I_P \quad (1d)$$

$$555 \quad \frac{dV}{dt} = \pi I_P - \gamma V \quad (1e)$$

$$556 \quad \text{where } \begin{cases} m(t) = 0 & t < \tau \\ m(t) = m & t \geq \tau \end{cases} \quad (1f)$$

557

558 To estimate parameter values, we fit the model to viral load data from the NBA cohort  
 559 using a mixed-effect population approach implemented in Monolix. Details on the  
 560 model selection and fitting process can be found in Owens et al<sup>26</sup>. Information about  
 561 parameter distributions and the error model is provided in **Table S1**.

562 We start the simulations with  $10^7$  susceptible cells. The initial value of the refractory  
 563 cells is assumed to be zero since the interferon signaling is not active prior to infection.  
 564 We further assume there are no infected cells (eclipse or productive) at the beginning of  
 565 the infection. We fix the level of inoculum ( $V_0$ ) at 97 copies/ml for each individual.

566 To resolve identifiability issues, we fixed two parameter values, setting the inverse of  
 567 the eclipse phase duration to  $\kappa = 4$ , and the rate of clearance of virions to  $\gamma = 15$ <sup>26</sup>.

## 568 **PK model**

569 We used a two-compartmental PK model which includes the amount of drug in the GI  
 570 tract ( $A_{GI}$ ), the plasma compartment ( $A_p$ ), and the lung ( $A_L$ ). The drug is administered  
 571 orally, passes through the GI tract and gets absorbed into the blood at the rate  $\kappa_a$ . The  
 572 drug then transfers from the blood into the peripheral compartment (or the lung) at the  
 573 rate  $\kappa_{PL}$ . The metabolized drug transfers back into the plasma at the rate  $\kappa_{LP}$  from  
 574 where it clears from the body at the rate  $\kappa_{CL}$ . The model in the form of ordinary  
 575 differential equations is written as,

$$576 \quad \frac{dA_{GI}}{dt} = -\kappa_a A_{GI} \quad (2a)$$

$$577 \quad \frac{dA_p}{dt} = \kappa_a A_{GI} + \kappa_{LP} A_L - (\kappa_{CL} + \kappa_{PL}) A_p \quad (2b)$$

$$578 \quad \frac{dA_L}{dt} = \kappa_{PL} A_p - \kappa_{LP} A_L \quad (2c)$$

579

580 We used Monolix and a mixed-effect population approach to estimate the parameters  
 581 and their standard deviations. With the initial condition of ( $A_{GI} = Dose$ ,  $A_p = 0$ ,  $A_L =$   
 582  $0$ ); we fit  $C_p = \frac{A_p}{Vol}$  to the plasma concentration data where  $Vol$  is the estimated plasma  
 583 volume. Details on parameter distributions and the error model provided in **Table S2**.

584

## 585 **PD model**

586 For the pharmacodynamics model we used Hill equation,  $\epsilon(t) = \frac{E_{max}C(t)^n}{C(t)^n + IC_{50}^n}$ , where  $C(t)$   
587 is the drug's concentration in plasma,  $E_{max}$  is the maximum efficacy,  $n$  is the Hill  
588 coefficient, and  $IC_{50}$  is the drug concentration in plasma required for 50% efficacy. We  
589 used least-squared fitting to obtain the three parameters ( $E_{max}$ ,  $n$ , and  $IC_{50}$ ) and their  
590 standard deviations. The average drug efficacy is measured using,

$$591 \quad E_{ave} = \frac{1}{t_{start} - t_{end}} \int_{t_{start}}^{t_{end}} \epsilon(t) dt \quad (3)$$

592 Where  $t_{start}$  and  $t_{end}$  are the treatment start day and end day, respectively.

593

## 594 Combined PKPD and VL models

595 The plasma concentration of nirmatrelvir obtained from the PK model is used in the PD  
596 model to obtain time-dependent efficacy.  $\epsilon(t)$ , then, is used to reduce viral production  
597 rate,  $\pi$ , with the factor of  $(1 - \epsilon(t))$ . Equation 1e is written as,

$$598 \quad \frac{dv}{dt} = (1 - \epsilon(t))\pi I_p - \gamma V \quad (4)$$

## 599 Fitting the combined model to individual viral load data in the PLATCOV trial

600 We used the population mixed-effect approach and Monolix to estimate each  
601 individual's viral dynamics parameters and the potency reduction factor (prf). Due to  
602 the lack of data from the initial phase of infection in the PLATCOV trial, we include  
603 the data from Omicron-infected individuals in the NBA cohort to inform the model  
604 about the initial phase of infection. We fixed the PK parameters to the estimated  
605 population values (**Table S2**), and the PD parameters other than  $IC_{50}$  to the *in vitro*  
606 estimated population values (**Table S4**). We used the study category (NBA vs  
607 PLATCOV) as a covariate for  $t_0$  (timing of infection) and  $\tau$  (timing of the adaptive  
608 immune response) since the first recorded positive test is likely much later for the  
609 clinical trials. In the NBA study, samples were collected almost daily regardless of  
610 symptoms often leading to pre-symptomatic detection, while in the PLATCOV study,  
611 the baseline measurement occurred after symptom onset, trial enrollment and consent.

## 612 Construction of a virtual cohort

613 To generate a cohort for our simulated clinical trials, we randomly selected 400  
614 individuals (for each arm of the simulated trials) from the unvaccinated symptomatic  
615 subpopulation of the NBA cohort for EPIC-HR and vaccinated with Omicron infection  
616 for PLATCOV and used their individual viral load parameters estimated by fitting our  
617 viral dynamics model to the data. A sample size of  $n=400$  (out of 822 vaccinated  
618 individuals with Omicron infection) was used to mimic a large-scale clinical trial and  
619 maintain relatively low overlap between virtual cohorts used in each arm of the  
620 simulations and between different simulations. Since the time of symptom onset is not  
621 available for all individuals in the NBA data, we randomly drew an incubation period  
622 for each individual from gamma distributions with variant-specific parameters  
623 estimated by Gamiche et al.<sup>27</sup> The start of treatment relative to symptom onset was  
624 randomly selected according to a uniform distribution, except when constructing **Fig. 8**.  
625 The PK parameters of each simulated individual were randomly drawn from lognormal  
626 distributions, for which estimated mean and standard deviation were inferred from the  
627 PK data. The relevant dose in each scenario was added to the  $A_{GI}$  compartment (the  
628 absorption equation) of the PK model (**eq 2a**) at each dosing timepoint ( $t=0, 0.5, 1, 1.5,$   
629  $\dots, 4.5$  days). For all doses, we used the PK parameter distributions estimated for 250

630 mg since our analysis showed they are dose-independent. PD parameters were also  
631 randomly drawn from a normal distribution with the estimated mean and standard  
632 deviation. The standard deviation of the PD parameters represents the accuracy of the  
633 assays and not individual variability. The individual potency reduction factors were  
634 also drawn from a lognormal distribution with estimated mean and standard deviation  
635 obtained from fitting the model to the individual viral load data of PLATCOV study.

### 636 Potency reduction factor (prf)

637 The prf is defined as,

$$638 \text{ prf} = \frac{IC_{50,in vivo}}{IC_{50,in vitro}} \quad (5)$$

639

640 We estimated the prf by maximizing  $R^2$  when fitting the change in viral load of the  
641 treatment arm of our simulation to the data from the treatment arm of the clinical trial.

### 642 Measuring rebound probability

643 A viral load rebound in the treatment arm was defined when the viral load at any time  
644 after treatment ended exceeded the viral load at the end of the treatment by 1 log. In the  
645 control group, viral rebound was defined in patients who had at least two peaks with  
646 maximum height of 1000 copies/ml in their viral load trajectories and the second peak  
647 was 1 log higher than its preceding local minimum (**Fig S7**).

648

649

### 650 References

651

652 Hammond, J. *et al.* Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. *N Engl J Med* **386**,  
653 1397–1408 (2022).

654 Emergency Use Authorization for Paxlovid (nirmatrelvir tablets co-packaged with ritonavir tablets) Center for  
655 Drug Evaluation and Research (CDER) Review. *Food and Drug Administration* (2021).

656 Khunte, M., Kumar, S., Salomon, J. A. & Bilinski, A. Projected COVID-19 mortality reduction from paxlovid  
657 rollout. *JAMA Health Forum* **4**, E230046 (2023).

658 FDA approves first oral antiviral for treatment of COVID-19 in adults. *Food and Drug Administration*  
659 [https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-antiviral-treatment-covid-19-](https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-antiviral-treatment-covid-19-adults)  
660 [adults](https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-antiviral-treatment-covid-19-adults).

661 Schilling, W. H. K. *et al.* Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with  
662 early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial. *Lancet*  
663 *Infect Dis* **24**, 35–45 (2023).

664 Pandit, J. A. *et al.* The Coronavirus disease 2019 rebound study: a prospective cohort study to evaluate viral and  
665 symptom rebound differences in participants treated with nirmatrelvir plus ritonavir versus untreated controls.  
666 *Clinical Infectious Diseases* **77**, 25–31 (2023).

667 Wong, C. K. H. *et al.* Optimal timing of nirmatrelvir/ritonavir treatment after COVID-19 symptom onset or  
668 diagnosis: target trial emulation. *Nat Commun* **14**, (2023).

669 Wang, L. *et al.* COVID-19 rebound after Paxlovid and Molnupiravir during January–June 2022. *medRxiv* (2022)  
670 doi:10.1101/2022.06.21.22276724.

671 Anderson, A. S., Caubel, P. & Rusnak, J. M. Nirmatrelvir–ritonavir and viral load rebound in Covid-19. *N Engl J*  
672 *Med* **387**, 1047–1049 (2022).

673 Pfizer shares top-line results from phase 2/3 EPIC-PEP study of PAXLOVID™ for post-exposure prophylactic  
674 use. *Pfizer* [https://www.pfizer.com/news/press-release/press-release-detail/pfizer-shares-top-line-results-phase-](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-shares-top-line-results-phase-23-epic-pep-study)  
675 [23-epic-pep-study](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-shares-top-line-results-phase-23-epic-pep-study).

676 Merck provides update on phase 3 MOVE-AHEAD trial evaluating LAGEVRIO™ (molnupiravir) for post-  
677 exposure prophylaxis for prevention of COVID-19 - Merck.com. [https://www.merck.com/news/merck-provides-](https://www.merck.com/news/merck-provides-update-on-phase-3-move-ahead-trial-evaluating-lagevrio-molnupiravir-for-post-exposure-prophylaxis-for-prevention-of-covid-19/)  
678 [update-on-phase-3-move-ahead-trial-evaluating-lagevrio-molnupiravir-for-post-exposure-prophylaxis-for-](https://www.merck.com/news/merck-provides-update-on-phase-3-move-ahead-trial-evaluating-lagevrio-molnupiravir-for-post-exposure-prophylaxis-for-prevention-of-covid-19/)  
679 [prevention-of-covid-19/](https://www.merck.com/news/merck-provides-update-on-phase-3-move-ahead-trial-evaluating-lagevrio-molnupiravir-for-post-exposure-prophylaxis-for-prevention-of-covid-19/).

- 680 Hirsch, C. *et al.* SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19. *Cochrane Database*  
681 *Syst Rev* Art. No.: CD014945 (2022) doi:10.1002/14651858.CD014945.PUB2.
- 682 O'Brien, M. P. *et al.* Effect of subcutaneous Casirivimab and Imdevimab antibody combination vs placebo on  
683 development of symptomatic COVID-19 in early asymptomatic SARS-CoV-2 infection: a randomized clinical  
684 trial. *JAMA* **327**, 432–441 (2022).
- 685 O'Brien, M. P. *et al.* Subcutaneous REGEN-COV antibody combination to prevent Covid-19. *N Engl J Med* **385**,  
686 1184–1195 (2021).
- 687 Herman, G. A. *et al.* Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of  
688 COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial. *Lancet Infect Dis* **22**,  
689 1444–1454 (2022).
- 690 Su, K. *et al.* A quantitative model used to compare within-host SARS-CoV-2, MERS-CoV, and SARS-CoV  
691 dynamics provides insights into the pathogenesis and treatment of SARS-CoV-2. *PLoS Biol* **19**, e3001128 (2021).
- 692 Wang, S. *et al.* Modeling the viral dynamics of SARS-CoV-2 infection. *Math Biosci* **328**, 108438 (2020).
- 693 Perelson, A. S. & Ke, R. Mechanistic modeling of SARS-CoV-2 and other infectious diseases and the effects of  
694 therapeutics. *Clin Pharmacol Ther* **109**, 829–840 (2021).
- 695 Sanche, S. *et al.* A simple model of COVID-19 explains disease severity and the effect of treatments. *Sci Rep* **12**,  
696 14210 (2022).
- 697 Czuppon, P. *et al.* Success of prophylactic antiviral therapy for SARS-CoV-2: Predicted critical efficacies and  
698 impact of different drug-specific mechanisms of action. *PLoS Comput Biol* **17**, e1008752 (2021).
- 699 Gonçalves, A. *et al.* Timing of antiviral treatment initiation is critical to reduce SARS-CoV-2 viral load. *CPT*  
700 *Pharmacometrics Syst Pharmacol* **9**, 509–514 (2020).
- 701 Iwanami, S. *et al.* Detection of significant antiviral drug effects on COVID-19 with reasonable sample sizes in  
702 randomized controlled trials: A modeling study. *PLoS Med* **18**, 25 (2021).
- 703 Goyal, A., Cardozo-Ojeda, E. F. & Schiffer, J. T. Potency and timing of antiviral therapy as determinants of  
704 duration of SARS-CoV-2 shedding and intensity of inflammatory response. *Sci Adv* **6**, (2020).
- 705 Fumagalli, V. *et al.* Nirmatrelvir treatment of SARS-CoV-2-infected mice blunts antiviral adaptive immune  
706 responses. *EMBO Mol Med* **15**, e17580 (2023).
- 707 Perelson, A. S., Ribeiro, R. M. & Phan, T. An explanation for SARS-CoV-2 rebound after Paxlovid treatment.  
708 *medRxiv* (2023) doi:10.1101/2023.05.30.23290747.
- 709 Owens, K., Esmaceli, S. & Schiffer, J. T. Heterogeneous SARS-CoV-2 kinetics due to variable timing and  
710 intensity of immune responses. *JCI Insight* (2024) doi:10.1172/JCI.INSIGHT.176286.
- 711 Galmiche, S. *et al.* SARS-CoV-2 incubation period across variants of concern, individual factors, and  
712 circumstances of infection in France: a case series analysis from the ComCor study. *Lancet Microbe* **4**, E409–  
713 E417 (2023).
- 714 Finch, C. L. *et al.* Formulation, stability, pharmacokinetic, and modeling studies for tests of synergistic  
715 combinations of orally available approved drugs against Ebola virus in vivo. *Microorganisms* **9**, 566 (2021).
- 716 Mayer, B. T. *et al.* Optimizing clinical dosing of combination broadly neutralizing antibodies for HIV prevention.  
717 *PLoS Comput Biol* **18**, (2022).
- 718 Edelstein, G. E. *et al.* SARS-CoV-2 virologic rebound with nirmatrelvir-ritonavir therapy. *medRxiv*  
719 2023.06.23.23288598 (2023) doi:10.1101/2023.06.23.23288598.
- 720 Schiffer, J. T., Swan, D. A., Corey, L. & Wald, A. Rapid viral expansion and short drug half-life explain the  
721 incomplete effectiveness of current herpes simplex virus 2-directed antiviral agents. *Antimicrob Agents*  
722 *Chemother* **57**, 5820–5829 (2013).
- 723 Reeves, D. B. *et al.* Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated  
724 Prevention (AMP) trials. *PLoS Comput Biol* **16**, (2020).
- 725 Schiffer, J. T. *et al.* Mathematical modeling of herpes simplex virus-2 suppression with pritelivir predicts trial  
726 outcomes. *Sci Transl Med* **8**, (2016).
- 727 Greenfield, S. R. *et al.* Species differences in plasma protein binding of the severe acute respiratory syndrome  
728 coronavirus 2 (SARS-CoV-2) main protease inhibitor nirmatrelvir. *Xenobiotica* **53**, 12–24 (2023).
- 729 Hau, R. K., Wright, S. H. & Cherrington, N. J. PF-07321332 (Nirmatrelvir) does not interact with human ENT1 or  
730 ENT2: Implications for COVID-19 patients. *Clin Transl Sci* **15**, 1599–1605 (2022).
- 731 Wong, C. K. H. *et al.* Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in  
732 Hong Kong: a population-wide retrospective cohort study. *Lancet Infect Dis* **23**, 683–695 (2023).
- 733 Pandit, J. A. *et al.* The Coronavirus Disease 2019 Rebound Study: A Prospective Cohort Study to Evaluate Viral  
734 and Symptom Rebound Differences in Participants Treated With Nirmatrelvir Plus Ritonavir Versus Untreated  
735 Controls. *Clin Infect Dis* **77**, (2023).
- 736 Zuckerman, N. S., Bucris, E., Keidar-Friedman, D., Amsalem, M. & Brosh-Nissimov, T. Nirmatrelvir  
737 Resistance—de Novo E166V/L50V Mutations in an Immunocompromised Patient Treated With Prolonged  
738 Nirmatrelvir/Ritonavir Monotherapy Leading to Clinical and Virological Treatment Failure—a Case Report.  
739 *Clinical Infectious Diseases* **ciad494**, (2023).



- 740 Xu, S. *et al.* Two-way pharmacodynamic modeling of drug combinations and its application to pairs of  
741 repurposed Ebola and SARS-CoV-2 agents. *Antimicrob Agents Chemother* (2024) doi:10.1128/AAC.01015-  
742 23/FORMAT/EPUB.
- 743 Jayk Bernal, A. *et al.* Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. *N Engl J Med* **386**,  
744 509–520 (2022).
- 745 Elias, K. M. *et al.* Viral clearance as a surrogate of clinical efficacy for COVID-19 therapies in outpatients: A  
746 systematic review and meta-analysis. *medRxiv* 2023.06.18.23291566 (2023) doi:10.1101/2023.06.18.23291566.
- 747 Gottlieb, R. L. *et al.* Early Remdesivir to prevent progression to severe Covid-19 in outpatients. *N Engl J Med*  
748 **386**, 305–315 (2022).
- 749 Carlin, A. F. *et al.* Virologic and immunologic characterization of Coronavirus disease 2019 recrudescence after  
750 Nirmatrelvir/Ritonavir treatment. *Clin Infect Dis* **76**, E530–E532 (2023).
- 751 Epling, B. P. *et al.* Clinical, virologic, and immunologic evaluation of symptomatic Coronavirus disease 2019  
752 rebound following Nirmatrelvir/Ritonavir treatment. *Clin Infect Dis* **76**, 573–581 (2023).
- 753 Boucau, J. *et al.* Characterization of virologic rebound following Nirmatrelvir-Ritonavir treatment for  
754 Coronavirus disease 2019 (COVID-19). *Clin Infect Dis* **76**, E526–E529 (2023).
- 755 Lai, C. C. & Hsueh, P. R. Coronavirus disease 2019 rebounds following nirmatrelvir/ritonavir treatment. *J Med*  
756 *Viro* **95**, (2023).
- 757 Hay, J. A. *et al.* Quantifying the impact of immune history and variant on SARS-CoV-2 viral kinetics and  
758 infection rebound: A retrospective cohort study. *Elife* **11**, (2022).
- 759 Rohatgi, A. WebPlotDigitizer. vol. 4.7 Software at <https://automeris.io/WebPlotDigitizer.html> (2024).
- 760 Singh, R. S. P. *et al.* Innovative randomized phase I study and dosing regimen selection to accelerate and inform  
761 pivotal COVID-19 trial of Nirmatrelvir. *Clin Pharmacol Ther* **112**, 101–111 (2022).
- 762 Owen, D. R. *et al.* An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19.  
763 *Science* **374**, 1586–1593 (2021).
- 764 Wagoner, J. *et al.* Combinations of host- and virus-targeting antiviral drugs confer synergistic suppression of  
765 SARS-CoV-2. *Microbiol Spectr* **10**, (2022).
- 766 Ke, R. *et al.* Daily longitudinal sampling of SARS-CoV-2 infection reveals substantial heterogeneity in  
767 infectiousness HHS Public Access. doi:10.5281/zenodo.6311388.
- 768
- 769
- 770

## 771 Acknowledgments

772

### 773 Funding:

774 National Institutes of Health (NIH) grants R01AI169427 (JTS)

775 National Institutes of Health (NIH) grants R01AI121129 (JTS)

776 National Institutes of Health (NIH) grants R01AI177512 (JTS, SJP)

777

### 778 Author contributions:

779 Conceptualization: JTS, SE, KO

780 Methodology: JTS, SE, KO

781 Software: SE, KO

782 Investigation: SJP, JW, SE, KO

783 Formal analysis: SE, KO

784 Writing – original draft: JTS, SE

785 Writing – review & editing: JTS, SE, KO, SJP, JW, JMW

786

### 787 Competing interests:

788 Authors declare that they have no competing interests.

789

### 790 Data availability:

791 The data analyzed in this work was previously published by Hay et al. and Schilling et  
792 al. and is available on github at

793 <https://github.com/gradlab/SC2-kinetics-immune-history> and  
794 <https://github.com/jwatowatson/PLATCOV-Molnupiravir/tree/V1.0>

795 Pharmacodynamics data is available on github at  
796 [https://github.com/sEsmaili/Covid\\_Rebound](https://github.com/sEsmaili/Covid_Rebound)

797

798 **Code availability:**


799 All codes and materials used in the analysis is available on github at  
800 [https://github.com/sEsmaili/Covid\\_Rebound](https://github.com/sEsmaili/Covid_Rebound)

801


802

803

804 **Figures and Tables**  
 805  
 806




807  
 808 **Fig. 1. Schematics of the viral dynamic model and nirmatrelvir PK-PD two**  
 809 **compartmental model.** (a) The viral dynamic model follows the dynamics of  
 810 susceptible cells (S), refractory cells (R), eclipse infected cells (I<sub>E</sub>), productively  
 811 infected cells (I<sub>P</sub>), and virus (V) and includes the early and late cytolytic T-cell immune  
 812 responses with rates  $\delta$  and  $m(t)$ .  $\beta$  is the infection rate,  $\phi$  is the rate of conversion of  
 813 susceptible cells to refractory cells, and  $\rho$  is the rate of reversion of refractory cells to  
 814 susceptible cells. Infected cells produce viruses at the rate  $\pi$ , and the free viruses are  
 815 cleared at the rate  $\gamma$ . (b) Two-compartmental PK model with oral administration of the  
 816 drug which models the amounts of the drug in gut tissue (A<sub>GI</sub>), plasma (A<sub>P</sub>), and the  
 817 tissue (A<sub>L</sub>).  $K_a$  is the rate of absorption of the drug from gut to plasma.  $K_{PL}$  and  $K_{LP}$   
 818 are the rates of transfer of the drug from plasma to the tissue and back, and  $K_{CL}$  is the rate  
 819 at which the drug clears from the body. Vol is the estimated plasma volume and  $C_P$  is  
 820 the drug concentration in plasma.  $\epsilon(C_P)$  is the drug efficacy that blocks viral production  
 821 and is calculated using the Hill equation:  $\frac{E_{max}C_P^n}{C_P^n + (prf * IC_{50})^n}$  where  $E_{max}$  is the maximum  
 822 efficacy,  $n$  is the Hill coefficient,  $IC_{50}$  is the concentration of drug *in vitro* at which  
 823 viral replication rate is reduced by 50%,  $prf$  is the potency reduction factor translating  
 824 the *in vitro* potency to *in vivo* potency.  
 825



**Fig. 2. Lower *in vivo* potency of nirmatrelvir relative to *in vitro* potency in EPIC-HR.** (a-b) mean (blue), individual (gray), and ranges (labeled dashed lines) of  $\log_{10}$  viral load drop from the baseline of individuals randomly selected from the NBA cohort treated with (a) placebo or (b) five days of nirmatrelvir / ritonavir 300 mg twice daily. The red dots were obtained by digitizing Fig 3a of Hammond et al.<sup>1</sup> and model fit was noted by closeness of blue lines to the red dots. (c)  $R^2$  of the fit of the 10 model simulations per prf to the viral load drop data in light blue and their mean in dark blue. The best model fit was at a potency reduction factor of 61. The horizontal boxplot in the lower panel shows the distribution of prf values at which  $R^2$  is maximum (mean = 61.8, median = 61, sd = 3.5). (d) Drug efficacy when prf=61. Average efficacy was 82% over the 5-day interval, with notable drops in antiviral efficacy at drug troughs. (e) Projected average drug efficacy when prf = 1 vs prf = 61. The drug with no potency reduction has nearly perfect efficacy (average efficacy of 99.99%) over 5 days and has a prolonged post-treatment effect. (f) Projected mean  $\log_{10}$  viral load drop from baseline of the control arm, treatment arm with prf=61, and treatment arm with prf=1.

826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845

846



**Fig. 3. Lower *in vivo* potency of nirmatrelvir relative to *in vitro* potency in PLATCOV. Method I: (a-b)** mean (blue), individual (gray), and ranges (labeled dashed lines) of log<sub>10</sub> viral load drop from the baseline of individuals randomly selected from the NBA cohort treated with (a) placebo or (b) five days of nirmatrelvir / ritonavir 300 mg twice daily. The empty and filled red circles are individual and mean viral load drop from baseline calculated from viral load data published by Schilling et al.<sup>5</sup>. Model fit was noted by closeness of blue lines to the filled red dots. (c)  $R^2$  of the fit of the 10 model simulations per prf to the viral load drop data in light blue and their mean in dark blue. The best model fit was at a potency reduction factor of 37. The horizontal boxplot in the lower panel shows the distribution of prf values at which  $R^2$  is maximum (mean = 36.6, median = 37, sd = 2.15). (d-e) distribution of log<sub>10</sub> viral load drop from baseline of simulated cohort and the 144 individuals in PLATCOV control arm (d) and treatment arm (e). Adjusted p-values (q-values) were calculated using Benjamini-Hochberg method and represent dissimilarity between observed and simulated distributions. **Method II: (f-g)** sample individual fits to PLATCOV trial participants in control (f) and treatment (g) arms. (h) distribution of estimated individual prf values (center line, median; box limits, upper and lower quartiles; whiskers, 1.5x interquartile range, blue dots are the prf values for each individual in the treatment arm). Remaining fits are in Figs S4 and S5.

847

848

849

850

851

852

853

854

855

856

857

858

859

860

861

862

863

864

865


866

867

868

869


870  
871  
872



873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887


**Fig. 4. Increasing the nirmatrelvir dose lowers short-term viral load but increases the probability of viral rebound.** In all scenarios, simulated treatment starts within the first 3 days post-symptoms. **(a)** log<sub>10</sub> viral load at days 2, 5, and 10 after the treatment start day with different doses. p-values were obtained by performing two-sided Mann-Whitney U-test between the 300 mg group and the others, and only p-values <0.01 are shown. Viral loads were only reduced by higher doses at days 2 and 5, but not day 10, except for 900 mg. **(b)** The probability of rebound for different doses. The error bars on each column are 95% confidence intervals. **(c)** Examples of viral load trajectories assuming different doses on 4 modeled individuals with equivalent timing of therapy and untreated viral kinetics. In all box plots, the center line is the median; box limits are upper and lower quartiles; whiskers show a 1.5x interquartile range.

888  
889



890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903


**Fig. 5. Early timing of therapy initiation is a key risk factor for viral rebound.** In all simulations, the dose was 300 mg twice daily for five days. PEP = 0 to 1 day after infection, early = 1-3 days after symptom onset, intermediate = 3-5 days after symptom onset, and late = 5-10 days after symptom onset. **(a)** log<sub>10</sub> viral load at days 2, 5, and 10 after the treatment start day with different treatment durations. p-values were obtained by performing two-sided Mann-Whitney U-test. In all box plots, the center line is the median; box limits are upper and lower quartiles; whiskers show a 1.5x interquartile range. **(b)** The probability of rebound for different treatment timing. The error bars on each column are 95% confidence interval **(c)** Samples of viral load trajectories assuming different treatment timing on 4 modeled individuals with equivalent untreated viral kinetics.



904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919

**Fig. 6. Prolonging treatment duration limits rebound probability.** In all simulations, treatment starts within the first 3 days post-symptoms and the dose was 300 mg twice daily. **(a)** log<sub>10</sub> viral load at days 2, 5, and 10 after the treatment start day with different treatment durations. p-values were obtained by performing two-sided Mann-Whitney U-test and only values <0.01 are shown. At day 10, the control group had equivalent viral loads to 2 days of treatment while 5 or 10 days of treatment significantly lowered viral load. In all box plots, the center line is the median; box limits are upper and lower quartiles; whiskers show a 1.5x interquartile range. **(b)** The probability of rebound for different treatment durations. The probabilities of rebound after 15 and 20 days of treatment were zero. The error bars on each column are 95% confidence interval. **(c)** Samples of viral load trajectories assuming different treatment durations on 4 modeled individuals with equivalent timing of therapy and untreated viral kinetics. Prolonging therapy often avoids rebound.






920  
921

922 **Fig. 7. Post-exposure prophylaxis requires more prolonged therapy than early**  
923 **symptomatic therapy to avoid viral rebound. (a) probability of rebound and**  
924 **(b) viral load at the end of the treatment as a function of treatment timing and**  
925 **duration.**

926

927



928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952

**Fig. 8. Early therapy preserves susceptible cells, limits refractory cells, does not eliminate all infected cells, and delays innate immune responses.**

Simulations are performed using time since infection as a variable rather than based on symptoms as in prior figures to eliminate the confounding impact of variable incubation period. **(a)** The top row shows the viral load of all individuals (in grey) and the average viral load (in blue). The middle row shows a less substantial depletion of susceptible cells (S, in green) and a lower generation of refractory cells (R, in red) with earlier therapy. The infected cells (I) are shown in blue. The highlighted area around each line (not visible) shows the 95% confidence interval. The bottom row shows the rate of production of refractory cells, which likely represents innate immune responses per day. The biphasic immune response with a lower initial peak and a second one after the end of the treatment is observed with early therapy and is present to a lesser extent in day 4 treated individuals. The highlighted areas show 95% confidence intervals. **(b)** Ratios of susceptible (S) to refractory cells (R) at the end of the 5-day treatment for different timings of treatment. **(c)** Per cell production rate of refractory cells at the end of the 5-day treatment for different timings of treatment. In all box plots, the center line is the median; box limits are upper and lower quartiles; whiskers show a 1.5x interquartile range. p-values were obtained by performing two-sided Mann-Whitney U-test (\*:  $0.01 < p \leq 0.05$ , \*:  $0.001 < p \leq 0.01$ , \*\*\*:  $0.0001 < p \leq 0.001$ , \*\*\*\*:  $0.00001 < p \leq 0.0001$ ).